Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06659614 · ClinicalTrials.gov registry record
Prostate Tissue BioBank
A clinical trial of Prostate Cancer and Genetic Predisposition, sponsored by Abramson Cancer Center at Penn Medicine.
- Recruiting
- Registry status
- 200
- Enrollment target
- 1
- Study location
NCT06659614 is a study of Prostate Cancer and Genetic Predisposition that is actively recruiting participants, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 200 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (67% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06659614, a study of Prostate Cancer and Genetic Predisposition, is actively recruiting participants, sponsored by Abramson Cancer Center at Penn Medicine.
- RECRUITING
- Registry status
- 200 participants
- Enrollment target
- 1
- Study location
Study Summary
Prostate cancer is also the most common cancer in men with inherited pathogenic variants in BRCA1 and BRCA2. Beyond BRCA1/2, other genes are known to increase the risk of prostate cancer, including ATM, TP53 and HOXB13. The investigators have shown that 5% of men diagnosed with prostate cancer localized to their prostate gland and up to 10-15% of patients with metastatic prostate cancer gland are carriers of an inherited gene mutation. The Prostate Tissue BioBank is a prospective study which aims to create a biorepository of prostate tissue samples from prostate biopsies and prostatectomies and matched germline DNA from pathogenic mutation carriers in addition to age-matched control samples. Our primary goal is to investigate prostate cancer development and treatment response in carriers of germline DNA repair mutations, as compared to non-carrier controls.
Conditions Studied
Study Locations (1)
Pennsylvania
- University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2024-01-01 |
| Est. Completion | 2034-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06659614
The ClinicalTrials.gov registry entry for NCT06659614 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (67% lower). The listed sponsor is Abramson Cancer Center at Penn Medicine, which has 402 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Prostate Cancer appearing as the primary indexed condition, and to 0 interventions.
NCT06659614 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT06659614 about?
NCT06659614 is a clinical study titled "Prostate Tissue BioBank". Prostate cancer is also the most common cancer in men with inherited pathogenic variants in BRCA1 and BRCA2. Beyond BRCA1/2, other genes are known to increase the risk of prostate cancer, including ATM, TP53 and HOXB13. The investigators have shown that 5% of men diagnosed with prostate cancer local...
What is the current status of trial NCT06659614?
This trial is currently recruiting. The enrollment target is 200 participants. The study started on 2024-01-01. Estimated completion is 2034-01.
What conditions does trial NCT06659614 study?
This clinical trial studies the following conditions: Prostate Cancer, Genetic Predisposition.
Who is sponsoring clinical trial NCT06659614?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06659614 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
Performance of Inherited Risk Assessment for Predicting Prostate Cancer From Prostate Biopsy
RECRUITING
-
Trial of Neoadjuvant Enoblituzumab vs SOC in Men With High-Risk Localized Prostate Cancer
RECRUITING · Phase 2
-
Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
RECRUITING
-
Improving Health Literacy in African-American Prostate Cancer Patients
RECRUITING · NA
-
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.